Olipass Corp

244460

Company Profile

  • Business description

    Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.

  • Contact

    16-4, 16 Beon-gil, Dongbaek Jungang-ro
    Ace Dongbaek Tower 20th Floor
    Giheung-gu
    Yongin17015
    KOR

    T: +82 3180608200

    https://www.olipass.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    27

Stocks News & Analysis

stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks

Bapcor is paying for the sins of its past

Shares plunged over 17% after reporting disappointing results.
stocks

Overvalued ASX share as market underestimates downside risks

Growth outlook solid, but upside more than priced in.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,324.6040.800.44%
CAC 408,206.0731.870.39%
DAX 4024,258.80427.811.80%
Dow JONES (US)46,706.58515.971.12%
FTSE 1009,403.5749.000.52%
HKSE25,858.83611.732.42%
NASDAQ22,990.54310.571.37%
Nikkei 22549,185.501,603.353.37%
NZX 50 Index13,344.9655.750.42%
S&P 5006,735.1371.121.07%
S&P/ASX 2009,031.9043.700.49%
SSE Composite Index3,863.8924.140.63%

Market Movers